Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
400.76 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 316.43 - 448.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 400.76 | USD |
Vertex Pharmaceuticals (VRTX) Options Flow Summary
Vertex Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
103.52B | 258.31M | - | 9.92B | 3.57B | 13.82 | 28.99 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Vertex Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 394.19 | 406.86 | 391.01 | 398.54 | 1,112,225 | 6.57 | 1.67% |
1 Month | 419.48 | 421.45 | 391.01 | 402.03 | 972,988 | -18.72 | -4.46% |
3 Months | 434.00 | 437.00 | 391.01 | 414.79 | 1,149,520 | -33.24 | -7.66% |
6 Months | 369.21 | 448.40 | 341.90 | 401.28 | 1,328,880 | 31.55 | 8.55% |
1 Year | 334.56 | 448.40 | 316.43 | 376.14 | 1,236,576 | 66.20 | 19.79% |
3 Years | 217.74 | 448.40 | 176.36 | 281.18 | 1,509,334 | 183.02 | 84.05% |
5 Years | 172.40 | 448.40 | 164.07 | 258.36 | 1,543,292 | 228.36 | 132.46% |
Vertex Pharmaceuticals Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |